SCHEMBL10150324

SCHEMBL10150324

CC1CCN(c2nc(-c3ccccc3O)nc3c2CC(C)CC3)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.53
KDM4E B2RXH2 5/20 0.53
MAPT P10636 4/20 0.53
TDP1 Q9NUW8 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
KMT2A Q03164 5/20 0.45
MEN1 O00255 4/20 0.45
SMAD3 P84022 1/20 0.44
CHEK2 O96017 1/20 0.44
HIF1A Q16665 1/20 0.43
TSHR P16473 5/20 0.42
ADORA1 P30542 1/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 3/20 0.40
ADORA2A P29274 1/20 0.39
LMNA P02545 3/20 0.39
HSD17B10 Q99714 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
USP2 O75604 2/20 0.39
PIK3CA P42336 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150318 0.93 SMAD3 (0.53) ALDH1A1KDM4EMAPTTDP1L3MBTL1
SCHEMBL10150319 0.92 SMAD3 (0.52) ALDH1A1KDM4EMAPTTDP1L3MBTL1
SCHEMBL10150326 0.91 MEN1 (0.57) ALDH1A1KDM4EMAPTTDP1L3MBTL1
SCHEMBL8297579 0.91 ALDH1A1 (0.53) ALDH1A1KDM4EMAPTTDP1L3MBTL1
SCHEMBL10150299 0.91 ALDH1A1 (0.53) ALDH1A1KDM4EMAPTTDP1L3MBTL1
SCHEMBL10150322 0.90 PIK3CA (0.52) ALDH1A1KDM4EMAPTTDP1L3MBTL1
SCHEMBL10150337 0.85 CHEK2 (0.43) ALDH1A1KDM4EMAPTTDP1L3MBTL1
SCHEMBL8299280 0.84 ALDH1A1 (0.46) ALDH1A1KDM4EMAPTTDP1L3MBTL1
SCHEMBL10150306 0.84 SMAD3 (0.53) ALDH1A1KDM4EMAPTTDP1L3MBTL1
SCHEMBL8297570 0.84 SMAD3 (0.53) ALDH1A1KDM4EMAPTTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS KCNQ1, KCNN2, KCNH3 ALDH1A1 3086/4885KDM4E 2477/4885MAPT 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.